Escalon® Medical Corp. and Modernizing Medicine, Inc. Announce Partnership for Offering Integrated EMR and Image Management

Escalon® Medical Corp. and Modernizing Medicine, Inc. Announce Partnership for
                 Offering Integrated EMR and Image Management

PR Newswire

WAYNE, Pa., Nov. 9, 2012

WAYNE, Pa., Nov. 9, 2012 /PRNewswire/ -- Escalon® Medical Corp. (Nasdaq: ESMC)
today announced the partnering of its Sonomed Escalon™ group with Modernizing
Medicine, Inc. to provide cloud-based end-to-end electronic medical records
(EMR) and image management solutions for ophthalmic practices. Seamless
integration of Sonomed Escalon's AXIS™ image management software and
Modernizing Medicine's Electronic Medical Assistant™ EMA Ophthalmology EMR
solution provides complete patient management from a single merged solution,
from coding and prescribing at the touch of a button to powerful exam image
review tools, and more. The companies will introduce the integrated solutions
at the American Academy of Ophthalmology's Annual Meeting in Chicago, IL
November 10-13, 2012.

"EMA Ophthalmology is a cloud-enabled EMR that is fast becoming one of the
industry's leading solutions due to its power, flexibility, ease of use, and
focus on improving clinical efficiency," noted Matthew Carnevale, Sonomed
Escalon's Chief Technology Officer. "Now added to that is unparalleled exam
image review capabilities and complete integration with nearly any diagnostic
imaging device."

"We are excited to save doctorseven more time with the addition of AXIS'
advanced integration of diagnostic images to patient records stored in
EMA,"said James Brooks, Executive Vice President of Sales & Marketing at
Modernizing Medicine. "Sonomed Escalon is an ideal partner for Modernizing
Medicine since both companies have demonstrated a commitment to making
accessible mobile offerings, especially on the iPad platform. With the
combined AXIS EMA Ophthalmology solution, ophthalmologists can now both review
diagnostic images such as OCT, fluorescein angiography, color fundus, and
others, and interpret the results of the exam directly on an iPad."

The partnership allows Modernizing Medicine and Escalon to offer their
respective products either as stand-alone solutions or as an integrated
package, depending upon the needs of particular clients. For more information,
visit www.modmed.comor www.sonomedescalon.com, or meet both companies at the
American Academy of Ophthalmology's Annual Meeting, booth #2771 for
Modernizing Medicine and #3238 for Sonomed Escalon.

About Modernizing Medicine

Modernizing Medicine is delivering the next generation of electronic medical
records (EMR) technology for the healthcare industry. Its Electronic Medical
Assistant™ (EMA) is a cloud-based specialty-specific EMR with a massive
library of built-in medical content, designed to save physicians time.
Available as a native iPad application or from any web-enabled Mac or PC, EMA
adapts to each provider's unique style of practice and is designed to
interface with over 400 different practice management systems. Today,
Modernizing Medicine provides specialty-specific offerings for the
dermatology, ophthalmology, optometry and plastic surgery markets, and to over
700 practices across the country.

About Escalon Medical Corp.

Founded in 1987, Escalon Medical Corp. (www.escalonmed.com) develops markets
and distributes ophthalmic diagnostic and surgical products. The Company seeks
to utilize strategic partnerships to enhance its development programs and also
seeks acquisitions to further expand its product offering to achieve critical
mass and better leverage the Company's distribution capabilities, although
such partnerships or acquisitions may or may not occur. The Company has
headquarters in Wayne, Pennsylvania and operations in Long Island, New York,
New Berlin, Wisconsin and Stoneham, Massachusetts.

Note: This press release contains statements that are considered
forward-looking under the Private Securities Litigation Reform Act of 1995,
including statements about the Company's future prospects. These statements
are based on the Company's current expectations and are subject to a number of
uncertainties and risks, and actual results may differ materially. The
uncertainties and risks include whether the Company is able to:

  oimplement its growth and marketing strategies, improve upon the operations
    of the Company business units, including the ability to make acquisitions
    and the integration of any acquisitions it may undertake, if any, of which
    there can be no assurance,
  ogrow our remaining ophthalmic business unit,
  oimplement cost reductions,
  ogenerate cash,
  oidentify, finance and enter into business relationships and acquisitions.

Other factors include uncertainties and risks related to:

  onew product development, commercialization, manufacturing and market
    acceptance of new products,
  omarketing acceptance of existing products in new markets,
  oresearch and development activities, including failure to demonstrate
    clinical efficacy,
  odelays by regulatory authorities, scientific and technical advances by the
    Company or third parties,
  ointroduction of competitive products,
  oability to reduce staffing and other costs and retain benefit of prior
    reductions
  othird party reimbursement and physician training, and
  ogeneral economic conditions.

Further information about these and other relevant risks and uncertainties may
be found in the Company's report on Form 10- K for year ended June 30, 2012,
and its other filings with the Securities and Exchange Commission, all of
which are available from the Securities and Exchange Commission as well as
other sources.



SOURCE Escalon Medical Corp.

Website: http://www.escalonmed.com
Contact: Richard J. DePiano, Chairman and CEO, +1-610-688-6830
 
Press spacebar to pause and continue. Press esc to stop.